Kaminer Keren, Rozenblat Tal, Shavit Itay, Finkel Inbar, Sasson Liat, Shimon Ilan, Hirsch Dania, Bachar Gideon, Robenshtok Eyal
Rabin Medical Center, Endocrinology & Metabolism Institute, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J Surg Oncol. 2025 Sep;132(4):633-639. doi: 10.1002/jso.70063. Epub 2025 Aug 6.
The utility of bilateral central compartment neck dissection (CCND) in patients with papillary thyroid carcinoma (PTC) and unilateral clinically node-positive disease remains debatable. Previous studies evaluated contralateral occult lymph-node metastases, which do not necessarily correlate with clinical recurrences. The objective of our study was to evaluate whether unilateral CCND is sufficient, specifically evaluating recurrence in the contralateral central neck.
Patients with PTC treated with total thyroidectomy and therapeutic unilateral CCND with at least 2 years of follow-up were included.
A total of 118 patients had unilateral therapeutic CCND, 58% with lateral neck dissection, 63% female, mean age of 48.1 ± 16.3 years. Mean follow-up was 6.2 ± 3.9 years, tumor size 17.6 ± 12 mm, 39% had minimal extrathyroidal extension (ETE) and 4% had gross ETE. A mean of 2.6 ± 2.6 LN were involved in the central compartment (size 9.4 ± 6.5 mm) and 4.4 ± 4 involved in the lateral neck (size 24.9 ± 14.3 mm). Recurrence on the ipsilateral side was detected in 6 patients (5%), while contralateral central compartment recurrence (the primary outcome) was detected in only 1 patient (1%).
In patients with PTC and unilateral clinically node-positive central compartment disease, unilateral therapeutic CCND is sufficient, with only 1% risk of recurrence in the contralateral central compartment.
双侧中央区颈淋巴结清扫术(CCND)在乳头状甲状腺癌(PTC)及单侧临床淋巴结阳性患者中的应用仍存在争议。既往研究评估了对侧隐匿性淋巴结转移情况,但其不一定与临床复发相关。本研究的目的是评估单侧CCND是否足够,特别是评估对侧中央区颈部的复发情况。
纳入接受全甲状腺切除术及治疗性单侧CCND且随访至少2年的PTC患者。
共有118例患者接受了单侧治疗性CCND,58%同时行侧颈淋巴结清扫,63%为女性,平均年龄48.1±16.3岁。平均随访时间为6.2±3.9年,肿瘤大小为17.6±12mm,39%有最小的甲状腺外侵犯(ETE),4%有肉眼可见的ETE。中央区平均有2.6±2.6枚淋巴结受累(大小为9.4±6.5mm),侧颈平均有4.4±4枚淋巴结受累(大小为24.9±14.3mm)。同侧复发6例(5%),而对侧中央区复发(主要观察指标)仅1例(1%)。
对于PTC及单侧临床淋巴结阳性的中央区疾病患者,单侧治疗性CCND足够,对侧中央区复发风险仅为1%。